Adriamycin and mitomycin C

Possible synergistic cardiotoxicity

A. U. Buzdar, S. S. Legha, C. K. Tashima, G. N. Hortobagyi, H. Y. Yap, Allan Norman Krutchik, M. A. Luna, G. R. Blumenschein

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

91 Patients with advanced breast cancer failing adriamycin (ADR)-containing combination chemotherapy were treated with a combination of mitomycin C (MMC) and megestrol acetate. Congestive heart failure (CHF) occurred in 14 (15.3%) of 91 MMC-treated patients compared to three (3.4%) of 89 patients treated with similar ADR-containing combination chemotherapy without MMC (P=0.01). The median time from the last dose of ADR to evidence of CHF was 8.5 months for the MMC group compared to 1.5 months for the other group. A significantly higher incidence of late onset of CHF implicates MMC as a possible cardiotoxic agent.

Original languageEnglish (US)
Pages (from-to)1005-1008
Number of pages4
JournalCancer Treatment Reports
Volume62
Issue number7
StatePublished - Dec 1 1978
Externally publishedYes

Fingerprint

Mitomycin
Doxorubicin
Heart Failure
Combination Drug Therapy
Cardiotoxins
Megestrol Acetate
Cardiotoxicity
Breast Neoplasms
Incidence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Buzdar, A. U., Legha, S. S., Tashima, C. K., Hortobagyi, G. N., Yap, H. Y., Krutchik, A. N., ... Blumenschein, G. R. (1978). Adriamycin and mitomycin C: Possible synergistic cardiotoxicity. Cancer Treatment Reports, 62(7), 1005-1008.

Adriamycin and mitomycin C : Possible synergistic cardiotoxicity. / Buzdar, A. U.; Legha, S. S.; Tashima, C. K.; Hortobagyi, G. N.; Yap, H. Y.; Krutchik, Allan Norman; Luna, M. A.; Blumenschein, G. R.

In: Cancer Treatment Reports, Vol. 62, No. 7, 01.12.1978, p. 1005-1008.

Research output: Contribution to journalArticle

Buzdar, AU, Legha, SS, Tashima, CK, Hortobagyi, GN, Yap, HY, Krutchik, AN, Luna, MA & Blumenschein, GR 1978, 'Adriamycin and mitomycin C: Possible synergistic cardiotoxicity', Cancer Treatment Reports, vol. 62, no. 7, pp. 1005-1008.
Buzdar AU, Legha SS, Tashima CK, Hortobagyi GN, Yap HY, Krutchik AN et al. Adriamycin and mitomycin C: Possible synergistic cardiotoxicity. Cancer Treatment Reports. 1978 Dec 1;62(7):1005-1008.
Buzdar, A. U. ; Legha, S. S. ; Tashima, C. K. ; Hortobagyi, G. N. ; Yap, H. Y. ; Krutchik, Allan Norman ; Luna, M. A. ; Blumenschein, G. R. / Adriamycin and mitomycin C : Possible synergistic cardiotoxicity. In: Cancer Treatment Reports. 1978 ; Vol. 62, No. 7. pp. 1005-1008.
@article{3e2defa9518d4fcd9ae308101eaf6183,
title = "Adriamycin and mitomycin C: Possible synergistic cardiotoxicity",
abstract = "91 Patients with advanced breast cancer failing adriamycin (ADR)-containing combination chemotherapy were treated with a combination of mitomycin C (MMC) and megestrol acetate. Congestive heart failure (CHF) occurred in 14 (15.3{\%}) of 91 MMC-treated patients compared to three (3.4{\%}) of 89 patients treated with similar ADR-containing combination chemotherapy without MMC (P=0.01). The median time from the last dose of ADR to evidence of CHF was 8.5 months for the MMC group compared to 1.5 months for the other group. A significantly higher incidence of late onset of CHF implicates MMC as a possible cardiotoxic agent.",
author = "Buzdar, {A. U.} and Legha, {S. S.} and Tashima, {C. K.} and Hortobagyi, {G. N.} and Yap, {H. Y.} and Krutchik, {Allan Norman} and Luna, {M. A.} and Blumenschein, {G. R.}",
year = "1978",
month = "12",
day = "1",
language = "English (US)",
volume = "62",
pages = "1005--1008",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Adriamycin and mitomycin C

T2 - Possible synergistic cardiotoxicity

AU - Buzdar, A. U.

AU - Legha, S. S.

AU - Tashima, C. K.

AU - Hortobagyi, G. N.

AU - Yap, H. Y.

AU - Krutchik, Allan Norman

AU - Luna, M. A.

AU - Blumenschein, G. R.

PY - 1978/12/1

Y1 - 1978/12/1

N2 - 91 Patients with advanced breast cancer failing adriamycin (ADR)-containing combination chemotherapy were treated with a combination of mitomycin C (MMC) and megestrol acetate. Congestive heart failure (CHF) occurred in 14 (15.3%) of 91 MMC-treated patients compared to three (3.4%) of 89 patients treated with similar ADR-containing combination chemotherapy without MMC (P=0.01). The median time from the last dose of ADR to evidence of CHF was 8.5 months for the MMC group compared to 1.5 months for the other group. A significantly higher incidence of late onset of CHF implicates MMC as a possible cardiotoxic agent.

AB - 91 Patients with advanced breast cancer failing adriamycin (ADR)-containing combination chemotherapy were treated with a combination of mitomycin C (MMC) and megestrol acetate. Congestive heart failure (CHF) occurred in 14 (15.3%) of 91 MMC-treated patients compared to three (3.4%) of 89 patients treated with similar ADR-containing combination chemotherapy without MMC (P=0.01). The median time from the last dose of ADR to evidence of CHF was 8.5 months for the MMC group compared to 1.5 months for the other group. A significantly higher incidence of late onset of CHF implicates MMC as a possible cardiotoxic agent.

UR - http://www.scopus.com/inward/record.url?scp=0018144412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018144412&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 1005

EP - 1008

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 7

ER -